ClinicalTrials.Veeva

Menu

NLR AND CRP Useful as Cost-Effective Preliminary Prognostic Markers in ST-Elevation Myocardial Infarction

S

Sohag University

Status

Enrolling

Conditions

STEMI

Treatments

Diagnostic Test: CBC
Diagnostic Test: C-reactive protein

Study type

Observational

Funder types

Other

Identifiers

NCT06491667
Soh-med-24-0614MS

Details and patient eligibility

About

Acute myocardial infarction (AMI) is a serious and fatal cardiovascular emergency and considered the leading cause of mortality worldwide.

Atherosclerosis of coronary arteries which takes decades to manifest clinically, is the primary predisposing pathologic factor responsible for the development of coronary heart disease It has been shown that A complex immune and inflammatory pathophysiological process is thought to be crucial for in the initiation and progression of atherosclerotic plaques.

Inflammation is one of the main mechanisms in the pathogenesis of atherosclerosis , Destabilization of chronic artery plaques and development of thrombosis, which are the main mechanisms in the pathophysiology of ST-segment elevation myocardial infarction (STEMI).

, and the interest to the evaluation of inflammatory biomarkers in coronary artery disease (CAD) has been increasing over the last decade .

Although numerous inflammatory markers, including troponin T/I, lactate dehydrogenase (LDH), and creatine kinase (CK-MB), are linked to worsened clinical outcomes in both ST elevation and non-ST elevation myocardial infarction (NSTEMI), there is an unmet need for a cost-effective biomarker for impoverished countries of the world .

The neutrophil-to-lymphocyte ratio (NLR), and C-reactive protein (CRP) ; has emerged as an important inflammatory markers for cardiovascular risk stratification.

And are relatively cheap inflammatory markers, can act as a bridge to mitigate the gap in assessing the cardiovascular risk and outcomes

Full description

Acute myocardial infarction (AMI) is a serious and fatal cardiovascular emergency and considered the leading cause of mortality worldwide.

  • Atherosclerosis of coronary arteries which takes decades to manifest clinically, is the primary predisposing pathologic factor responsible for the development of coronary heart disease

  • It has been shown that A complex immune and inflammatory pathophysiological process is thought to be crucial for in the initiation and progression of atherosclerotic plaques

  • Inflammation is one of the main mechanisms in the pathogenesis of atherosclerosis , Destabilization of chronic artery plaques and development of thrombosis, which are the main mechanisms in the pathophysiology of ST-segment elevation myocardial infarction (STEMI) .

    , and the interest to the evaluation of inflammatory biomarkers in coronary artery disease (CAD) has been increasing over the last decade .

  • Although numerous inflammatory markers, including troponin T/I, lactate dehydrogenase (LDH), and creatine kinase (CK-MB), are linked to worsened clinical outcomes in both ST elevation and non-ST elevation myocardial infarction (NSTEMI), there is an unmet need for a cost-effective biomarker for impoverished countries of the world

  • The neutrophil-to-lymphocyte ratio (NLR), and C-reactive protein (CRP) ;

  • has emerged as an important inflammatory markers for cardiovascular risk stratification.

  • And are relatively cheap inflammatory markers, can act as a bridge to mitigate the gap in assessing the cardiovascular risk and outcomes In patients with acute myocardial infarction.

  • Recent data indicates a strong independent relationship between increased complications after acute myocardial infarction in patients with a high NLR and high CRP level at admission and the initial post-hospitalization period.

  • Accordingly, we designed this study to assess the predictive value and prognosis of NLR and CRP in ST-elevation myocardial infarction (STEMI).

Enrollment

100 estimated patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Patients with age ≥18 years of either sex, with either increase in serum cardiac biomarkers or ECG are STEMI.

Exclusion criteria

  • Patients presenting with NSTEMI and unstable angina
  • Patients with any of these associated conditions that can affect NLR or CRP including
  • Inflammatory conditions such as collagen-vascular disorders
  • Acute or chronic infectious diseases.
  • Auto-immune and neoplastic diseases.
  • Chronic hepatic diseases.
  • Renal failure.
  • Thyroid disorders.
  • Previous valvular heart disease.

Trial design

100 participants in 2 patient groups

Elevated NLR and CRP level
Description:
Elevated NLR and CRP level
Treatment:
Diagnostic Test: C-reactive protein
Diagnostic Test: CBC
Normal NLR and CRP level
Description:
Elevated NLR and CRP level
Treatment:
Diagnostic Test: C-reactive protein
Diagnostic Test: CBC

Trial contacts and locations

1

Loading...

Central trial contact

Albair Y Kaiser, Resident; Sharaf El-DEEN Sh Abd-Allah, Professor

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems